Rapid Diagnosis of Sepsis

Plastic Surgical Nursing

Volumn 2, Issue 3, 2003, Pages 163-171

  Kost, Gerald J ^a   Tran, Nam K ^a   Louie, Richard F ^a   Tang, Zuping ^a   Woodruff, Ashley A ^a   Albertson, Timothy E ^b   Derlet, Robert W ^a   Azari, Rahman ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

activated protein C; microbial resistance; multiple organ dysfunction syndrome; polymerase chain reaction; sepsis; therapeutic turnaround time

Indexed keywords

EID: 85026180829     PISSN: 07415206     EISSN: 15501841     Source Type: Journal    
DOI: 10.1097/00134384-200309000-00003     Document Type: Article

References (41)

1. Balk RA, Ely EW, Goyette RE. Sepsis Handbook/National Initiative In Sepsis Education (NISE). Vanderbilt University Medical Center; 2001.
2. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States. Analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001; 29:1303-1310.
3. Bernard GR, Vincent J-L, Laterre P-F, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001; 344:699-709.
4. Bion JF. Is the gut responsible for multiple organ failure? Schweiz Med Wochenschr. 1999; 129:1600-1604.
5. Dhainaut J, Marin N, Mignon A, et al. Hepatic response to sepsis: interaction between coagulation and inflammatory processes. Crit Care Med. 2001; 29S:S42-S47.
6. Esmon CT. Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation. Crit Care Med. 2001; 29S:48-52.
7. Faust SN, Heyderman RS, Levin M. Coagulation in severe sepsis: a central role for thrombomodulin and activated protein C. Crit Care Med. 2001; 29S:62-68.
8. Foitzik T. Pancreatitis and nutrition. Significance of the gastrointestinal tract and nutrition for septic complications. Zentralbl Chir. 2001; 126:4-9.
9. Hack CE, Zeerleder S. The endothelium in sepsis: source of and target for inflammation. Crit Care Med. 2001; 29S:21-27.
10. Hinder F, Stubbe HD, Waurick R, et al. Role of nitric oxide in sepsis-associated pulmonary edema. Am J Respir Crit Care Med. 1999; 159:252-257.
11. Martin GS, Bernard GR. Airway and lung in sepsis. Intensive Care Med. 2001; 27S:63-79.
12. Matthay MA. Severe sepsis-a new treatment with both anticoagulant and anti-inflammatory properties. N Engl J Med. 2001; 344:759-762.
13. Neumann B, Zantl N, Veihelmann A, et al. Mechanisms of acute inflammatory lung injury induced by abdominal sepsis. Inter Immun. 1998; 11:217-227.
14. Nieuwenhuijzen GA, Goris RJ. The gut: the `motor' of multiple organ dysfunction syndrome? Curr Opin Clin Nutr Metab Care. 1999; 2:399-404.
15. Swank GM, Deitch EA. Role of the gut in multiple organ failure: bacterial translocation and permeability changes. World J Surg. 1996; 20:411-417.
16. Vallet B, Wiel E. Endothelial cell dysfunction and coagulation. Crit Care Med. 2001; 29S:36-41.
17. Kost G. Controlling economics, preventing errors, and optimizing outcomes in point-of-care testing. In: Kost GJ, ed. Principles & Practice of Point-of-Care Testing. Philadelphia: Lippincott Williams & Wilkins; 2002:577-600.
18. Gaut JP, Yeh GC, Tran HD, et al. Neutrophils employ the myeloperoxidase system to generate antimicrobial brominating and chlorinating oxidants during sepsis. PNAS. 2001; 98:11961-11966.
19. Oh-oka H, Fujisawa M, Okada H, et al. Differential involvement of reactive oxygen species and myeloperoxidase in oxygen-dependent killing of urinary tract bacterial isolates by polymorphonuclear leukocytes. Urol Res. 2001; 29:423-427.
20. Roche Diagnostic LightCycler. Available at: http://www.lightcycler-online.com/. Accessed September 2002.
21. Sloan LM, Hopkins MK, Mitchel S, et al. Multiplex LightCycler PCR assay for detection and differentiation of Bordetella pertussis and Bordetella parapertussis in nasophyaryngeal specimens. J Clin Microbiol. 2002; 40:96-100.
22. Cockerill FR. Rapid testing for streptococcal infection. How effective is it? Mayo Clinic and Mayo Medical School. Available at: http://www.aacc.org/access/rapid/presentation_files/frame.htm, 5 November 2002. Accessed November 10, 200.
23. Guven H, Altintop L, Baydin A. Diagnostic value of procalcitonin levels as an early indicator of sepsis. Am J Emerg Med. 2002; 20:202-206.
24. Jaffe RI, Lane JD, Bates CW. Real-time identification of Pseudomonas aeruginosa direct from clinical samples using and polymerase chain reaction (PCR). J Clin Lab Anal. 2001; 15:131-137.
25. Schmid A, Burchardi H, Clouth J, et al. Burden of illness imposed by severe sepsis in Germany. Eur J Health Econ. 2002; 3:77-82.
26. Letarte J, Longo CJ, Pelletier J, et al. Patient characteristics and costs of severe sepsis and septic shock in Quebec. J Crit Care. 2002; 17:39-49.
27. Mortelliti MP, Manning HL. Acute respiratory distress syndrome. 28. Am Fam Physician. 2002; 65:1823-1830.
28. Hamel MB, Phillips RS, Davis RB, et al. Outcomes and cost-effectiveness of ventilator support and aggressive care for patients with acute respiratory failure due to pneumonia or acute respiratory distress syndrome. Am J Med. 2000; 109:614-620.
29. Platt R, Adelson-Mitty J, Weissman L, et al. Resource utilization associated with initial hospital stay complicated by early onset group B streptococcal disease. Pediatr Infect Dis J. 1999; 18:529-533.
30. Haberland CA, Benize WB, Sanders GD. Perinatal screening for group B streptococci: cost-benefit analysis of rapid polymerase chain reaction. Pediatrics. 2002; 110:417-480.
31. Logsdon BA, Casto DT. Prevention of group B streptococcus infection in neonates. Ann Pharmacother. 1997; 31:897-906.
32. Fagon J-Y, Chastre J, Wolff M, et al. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. Ann Intern Med. 2000; 132:621-630.
33. Singh N, Rogers P, Atwood CW, et al. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. Ann J Respir Crit Care Med. 2000; 162:505-511.
34. Marron A, Carratala J, Gonzalez-Barca E, et al. Serious complications of bacteremia caused by Viridans Streptococci in neutropenic patients with cancer. Clin Infect Dis. 2000:1126-1130.
35. Rosenman M, Madsen K, Hui S, et al. Modeling administrative outcomes in fever and neutropenia: clinical variables significantly influence length of stay and hospital charges. J Pediatr Hematol Oncol. 2002; 24:263-268.
36. Morace G, Pagano L, Sanguinetti M, et al. PCR-Restriction enzyme analysis for detection of Candida DNA in blood from febrile patients with hematological malignancies. J Clin Microbiol. 1999; 37:1871-1875.
37. Van Den Berghe G, Wouters P, Verwaest C, et al. Intensive insulin therapy in critical ill patients. N Engl J Med. 2001; 345:1359-1367.
38. Ravven W. Infection rate from surgery reduce with oxygen. UCSF Childrens Hospital News. Available at: http://www.ucsfhealth.org/childrens/health_library/news/2000/01/9173.html, January 19, 2000 Accessed November 10, 2002.
39. Paxton A. Window watchers-eyeing NAT's impact. CAP Today. 2002;16:1,12,14,16-20.
40. Griffith JR, Alexander JA, Jelink RC. Measuring comparative hospital performance. J Healthc Manag. 2002; 47:411-457.
41. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Eng J Med. 2001; 345:1368-1377.